Mylan announces the acquistion of the U.S. commercialization, marketing and intellectual property rights of Arixtra.
Arixtra is an injection designed for the prophylaxis of deep vein thrombosis.
Arixtra, which is part of Aspen Global Incorporated, is already being sold through an interim distribution arrangement.
Mylan will also acquire the rights to the authorized generic version of Arixtra.
Apotex, which is currently selling the generic version of the drug, will be transitioning to Mylan Institutional by the end of 2014.
Arixtra is also known as fondaparinux sodium.
Mylan will pay Aspen $225 million once the transaction is complete.
An additional $75 million will be held in escrow and released under certain conditions.
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Pharma and Biotech M&A Trends 2009-2014
View: M&A Scorecard in CP Insight– view top life science partnering deals by value
View: Partnering’s DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity